In this review:
auto-HCT therapies in high-risk MM
Lenalidomide maintenance after ASCT in MM
Syngeneic vs auto-HCT transplantation for MM
Carfilzomib in newly diagnosed MM patients
Venetoclax for relapsed/refractory MM
Natural history of t(11;14) MM
HCT approaches in primary plasma cell leukaemia
Denosumab vs zoledronic acid for bone disease in MM
Rates of upfront auto-HCT transplantation
Australia and NZ myeloma and related diseases registry
Hyperelderly MM
Please login below to download this issue (PDF)